Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
CSE:NOVO B
Price:
903.3 DKK
-1.05%
Market Closed
Updated:
May 19, 2024
Novo Nordisk A/S
Accounts Receivables
|
Novo Nordisk A/S
Accounts Receivables Peer Comparison
Comparables:
HLUN A
ALK B
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Accounts Receivables
kr57B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Accounts Receivables
kr3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Accounts Receivables
kr816m
|
CAGR 3-Years
14%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
See Also
What is Novo Nordisk A/S's Accounts Receivables?
Accounts Receivables
57B
DKK
57B
DKK
Based on the financial report for Mar 31, 2024, Novo Nordisk A/S's Accounts Receivables amounts to 57B DKK.
What is Novo Nordisk A/S's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
18%
18%
Over the last year, the Accounts Receivables growth was 13%. The average annual Accounts Receivables growth rates for Novo Nordisk A/S have been 27% over the past three years , 22% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
